Publications
- Initial experience of Czech MDS Group with 5-azacytidine in patients with high risk myelodysplastic syndromes (IPSS intermediate II and high), acute myeloid leukaemia with less than 30% myeloblasts and chronic myelomonocytic leukaemia II2013 | First Faculty of Medicine
- TP53 mutations in myelodysplastic syndrome is significantly correlated with deletion of the long arm 5.chromozomu (5q-) and usually has a negative prognostic value (meaning TP53 examination in the era of lenalidomide)2013 | First Faculty of Medicine
- Molecular cytogenetic analysis of chromosome 11 breakpoints in acute myeloid leukemiaPublication without faculty affiliation
- Genomic imbalances in 73 patients with MDS and complex karyotypesPublication without faculty affiliation
- True monosomy of chromosome 5 is presumably not an isolated cytogenetic entity in MDSPublication without faculty affiliation
- Attenuated cell cycle and DNA damage response transcriptome signatures and overrepresented cell adhesion processes imply accelerated progression in patients with lower-risk myelodysplastic neoplasms2024 | First Faculty of Medicine, Faculty of Physical Education and Sport, Faculty of Science
- Expression of circular RNAs in myelodysplastic neoplasms and their association with mutations in the splicing factor gene SF3B12023 | Faculty of Science, Central Library of Charles University
- Luspatercept – a new contribution to the therapy of anaemia in patients with myelodysplastic syndrome2023 | First Faculty of Medicine
- Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial2023 | First Faculty of Medicine
- The benefit of luspatercept in the treatment of low‑risk myelodysplastic syndrome – case report2023 | First Faculty of Medicine
Loading network view...